
• Our work shows that WTX-124, a pro-drug containing wild-type IL-2, is selectively processed and activated in tumors and is efficacious in murine models, even in the presence of regulatory T cells • WTX-124 activity is dependent on the processing of the pro-drug as a non-cleavable version of WTX-124 (WTX-124-NC) is not efficacious in our ...
In this study, we discovered that loss of WTX could activate CDC42 through disrupting the interaction between CDC42 and its inhibitor Rho GDP-dissociation inhibitors (RhoGDIa), which promotes...
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes …
WTX-330 is being developed for the treatment of relapsed or refractory, advanced or metastatic solid tumors, or lymphomas, and is currently in clinical development (NCT05678998).
Discovery of a Conditionally Activated IL-2 that Promotes …
WTX 124 is an inducible IL-2 prodrug that is selectively activated in the tumor microenvironment. Administration of WTX-124 generates potent antitumor immunity by activating tumor-infiltrating lymphocytes while preventing the toxicity associated with systemic, high dose IL-2 treatment.
WTX-330, a conditionally activated IL-12 INDUKINETM therapy, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models
• WTX-124 is a tumor selective inducible IL-2 prodrug that generates significant anti-tumor activity in a CD8+ T Cell dependent manner • WTX -124 has a better therapeutic window than rhIL 2 or half life
NC Krav / WTx Combatives - New Student Sign Up
Complete Registration. Open Black Belt © 2025.
Our Approach | Werewolf Therapeutics Inc.
WTX-124 is designed to include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rβ/IL2Rγ interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
WTX-330 in Patients with Advanced or Metastatic Solid Tumors or …
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
pro-drug as a non-cleavable version of WTX-124 (WTX-124-NC) is not efficacious in our models • Mechanistically, WTX-124 induces intratumoral activation of NK cells and CD8+ T cells as well as a proinflammatory phenotype in Tregs, and generates long-term memory in treated animals • WTX-124 possesses good PK characteristics in mouse
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX …
WTX-124 exhibits approximately dose-proportional PK with very low levels of active IL-2 (<1% of prodrug). Tumor biopsies are being analyzed for changes in the frequency and functionality of tumor-infiltrating lymphocytes, PD-L1 expression, and immune cell gene expression.
AshevilleWX
Covering ever aspect of the weather in Asheville and the surrounding areas of Western North Carolina. Live webcams, weather radar, 5 day forecast, and in-depth model discussion can be found here and is produced by Meteorologist Hunter Ward.
Mir-454-3p induced WTX deficiency promotes hepatocellular …
Mar 21, 2022 · WTX (Wilms Tumor gene on X chromosome) is an X-linked tumor suppressor discovered in the Wilms tumor [9-11]. WTX forms a complex with β-TrCP2, β-catenin, APC, and AXIN1 to promote the ubiquitination of β-catenin protein, which inhibits the activation of WNT signaling pathway in Wilms tumors [12-14].
• WTX-330 is designed to be a first-in-class, systemically delivered, conditionally activated IL-12 INDUKINE™ molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma • Since human IL-12 is not active in mouse cells, an INDUKINE surrogate containing a chimeric IL-12 molecule was designed (mWTX-330)
Wilms Tumor Gene on X Chromosome (WTX) Inhibits Degradation of …
FAM123B/WTX/AMER1 (hereafter referred to as WTX) is located on the X chromosome and encodes a tumor suppressor protein that is lost or mutated in up to 30% of the cases of Wilms tumor, the most common pediatric kidney cancer (1–3).
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes …
Jul 5, 2023 · WTX-330 is being developed for the treatment of relapsed or refractory, advanced or metastatic solid tumors, or lymphomas, and is currently in clinical development (NCT05678998).
AshevilleWX
Jan 27, 2024 · Check out the most recent NAM3km simulated radar and snowfall projection. Tune in on Facebook and Youtube for a live update on the upcoming weather pattern at 4:30. I see 3 chances for snowfall over the next 10 days around WNC so buckle up, this warm weather is gone.
Key features of WTX-330 include peripheral blockade (green) of the IL-12–IL-12 receptor interaction to limit systemic toxicity, half-life extension (blue) for optimal exposure in tumors and conditional activation in the tumor microenvironment.
Ashevillewx-Meteorologist Hunter Ward - Facebook
Ashevillewx-Meteorologist Hunter Ward. 50,980 likes · 2,341 talking about this. Your place to get accurate weather updates for the WNC area and...
WTX-330 is an IL-12 INDUKINETM molecule that uses a prodrug strategy to leverage the favorable proinflammatory activities of this potent and pleiotropic cytokine to safely stimulate antitumor immune responses Enrollment in the dose escalation part of the WTX-330x2101 first-in-human study is presently ongoing Creating Powerful Proinflammatory